solo para uso en investigación
Cat. No.S7794
| Dianas relacionadas | ERK p38 MAPK Raf MEK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase |
|---|---|
| Otros JNK Inhibidores | CC-90001 SP600125 JNK-IN-8 Anisomycin (Flagecidin) JNK Inhibitor IX Tanzisertib Hydrochloride (CC-930) Polyphyllin I DTP3 BI-78D3 Bentamapimod (AS602801) |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| NB7 | Growth inhibition assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50=2.27473μM | SANGER | |||
| LB2241-RCC | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=6.57739μM | SANGER | |||
| NCI-H1299 | Growth inhibition assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50=13.2019μM | SANGER | |||
| BV-173 | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=14.0505μM | SANGER | |||
| HPAF-II | Growth inhibition assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50=14.5873μM | SANGER | |||
| RS4-11 | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=16.6795μM | SANGER | |||
| EW-1 | Growth inhibition assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50=17.1883μM | SANGER | |||
| NCI-H1581 | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=17.2588μM | SANGER | |||
| SK-PN-DW | Growth inhibition assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50=17.9485μM | SANGER | |||
| KP-4 | Growth inhibition assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50=19.1087μM | SANGER | |||
| DU-145 | Growth inhibition assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50=19.8748μM | SANGER | |||
| ACHN | Growth inhibition assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50=20.6213μM | SANGER | |||
| A172 | Growth inhibition assay | Inhibition of human A172 cell growth in a cell viability assay, IC50=21.263μM | SANGER | |||
| HuO-3N1 | Growth inhibition assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50=21.4318μM | SANGER | |||
| QIMR-WIL | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=22.3274μM | SANGER | |||
| NCI-H1650 | Growth inhibition assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50=22.7873μM | SANGER | |||
| SW1088 | Growth inhibition assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50=23.1641μM | SANGER | |||
| Mewo | Growth inhibition assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50=23.3997μM | SANGER | |||
| NCI-H1355 | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=24.6365μM | SANGER | |||
| SK-LU-1 | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=27.058μM | SANGER | |||
| KYSE-70 | Growth inhibition assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50=27.125μM | SANGER | |||
| KP-N-YS | Growth inhibition assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50=27.5706μM | SANGER | |||
| HTC-C3 | Growth inhibition assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50=27.7345μM | SANGER | |||
| NB17 | Growth inhibition assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50=27.9113μM | SANGER | |||
| GOTO | Growth inhibition assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50=27.9415μM | SANGER | |||
| BEN | Growth inhibition assay | Inhibition of human BEN cell growth in a cell viability assay, IC50=29.865μM | SANGER | |||
| HMV-II | Growth inhibition assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50=30.1553μM | SANGER | |||
| SF295 | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50=32.156μM | SANGER | |||
| MPP-89 | Growth inhibition assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=33.5199μM | SANGER | |||
| LCLC-103H | Growth inhibition assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50=34.2223μM | SANGER | |||
| MN-60 | Growth inhibition assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50=36.0139μM | SANGER | |||
| BB65-RCC | Growth inhibition assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=36.1528μM | SANGER | |||
| BHY | Growth inhibition assay | Inhibition of human BHY cell growth in a cell viability assay, IC50=36.9645μM | SANGER | |||
| SK-MEL-3 | Growth inhibition assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=37.7324μM | SANGER | |||
| NY | Growth inhibition assay | Inhibition of human NY cell growth in a cell viability assay, IC50=37.7592μM | SANGER | |||
| CAL-72 | Growth inhibition assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=37.9289μM | SANGER | |||
| ES3 | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=38.1949μM | SANGER | |||
| NBsusSR | Growth inhibition assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=39.3132μM | SANGER | |||
| NB10 | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50=40.1731μM | SANGER | |||
| ChaGo-K-1 | Growth inhibition assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50=41.1576μM | SANGER | |||
| KYSE-450 | Growth inhibition assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50=41.4514μM | SANGER | |||
| SK-MEL-1 | Growth inhibition assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50=41.9927μM | SANGER | |||
| PC-3 | Growth inhibition assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50=42.2752μM | SANGER | |||
| KARPAS-299 | Growth inhibition assay | Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50=44.5948μM | SANGER | |||
| DBTRG-05MG | Growth inhibition assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50=44.6546μM | SANGER | |||
| HCC1806 | Growth inhibition assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50=45.2169μM | SANGER | |||
| NCI-H2009 | Growth inhibition assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=45.2843μM | SANGER | |||
| HCC2157 | Growth inhibition assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50=45.7976μM | SANGER | |||
| EM-2 | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=47.4011μM | SANGER | |||
| DOK | Growth inhibition assay | Inhibition of human DOK cell growth in a cell viability assay, IC50=48.3877μM | SANGER | |||
| HepG2 | Function assay | Inhibition of cJun phosphorylation in HepG2 cell line, Ki=0.004μM | 16759099 | |||
| HepG2 | Function assay | Inhibition of cJun phosphorylation in HepG2 cell line, EC50=0.92μM | 16759099 | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 356.38 | Fórmula | C18H20N4O4 |
Almacenamiento (Desde la fecha de recepción) | 3 years -20°C powder |
|---|---|---|---|---|---|
| Nº CAS | 894804-07-0 | -- | Almacenamiento de soluciones madre |
|
|
| Sinónimos | TCS JNK 6o | Smiles | CCOC1=C(C(=CC(=N1)NC(=O)CC2=C(C=CC(=C2)OC)OC)N)C#N | ||
|
In vitro |
DMSO
: 71 mg/mL
(199.22 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
JNK1
(Cell-free assay) 2 nM(Ki)
JNK2
(Cell-free assay) 4 nM(Ki)
JNK1
(Cell-free assay) 45 nM
JNK3
(Cell-free assay) 52 nM(Ki)
JNK2
(Cell-free assay) 160 nM
|
|---|---|
| In vitro |
JNK Inhibitor VIII (TCS-JNK-6a) se une de forma competitiva y reversible al sitio de ATP. Este compuesto demuestra un perfil de selectividad notable. Además, muestra cierta inhibición de la fosforilación de c-Jun en células HepG2. TCS-JNK-6o es un análogo 2,5-dimetoxi de este químico con la sustitución dimetoxi del anillo fenilo. Este compuesto muestra mayores ganancias en potencia. |
| Ensayo de quinasa |
Ser/Thr-cinasa
|
|
Los ensayos de Ser/Thr-cinasa se realizan utilizando una plataforma de ensayo radiactiva basada en FlashPlate. En este formato, el péptido sustrato biotinilado (2 μM), γ-[33P]-ATP (5 μM, 2 mCi/μmol), este compuesto (3-10000 nM en 2% de DMSO) y la enzima se incuban durante 1 h en un tampón que contiene 25 mM Hepes, pH 7.5, 1 mM DTT, 10 mM MgCl2, 100 μM Na3VO4 y 0.075 mg/mL Triton X-100, se detienen con 80 μL de tampón de parada que contiene 100 mM EDTA y 4 M NaCl, se transfieren a placas FlashPlate de 384 pocillos recubiertas con estreptavidina, que luego se lavan 3 veces y se leen usando un lector de microplacas TopCount.
|
|
| In vivo |
Se determinan los perfiles farmacocinéticos para JNK Inhibitor VIII (TCS-JNK-6o) en ratas Sprague-Dawley. Este compuesto muestra una vida media corta de aproximadamente 1 h, con un aclaramiento rápido y una biodisponibilidad apenas medible. Los estudios de incubación microsómica revelaron que el metabolismo oxidativo es muy rápido con este compuesto. |
Referencias |
Tel: +1-832-582-8158 Ext:3
Si tiene alguna otra consulta, por favor deje un mensaje.